Drug Profile
Tramadol - Aytu BioPharma
Alternative Names: BIO-301; DMI-7958; LI-301; LIF-301; Zertane™Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Enhance Lifesciences
- Developer Aytu BioScience
- Class Anisoles; Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Small molecules
- Mechanism of Action Adrenergic receptor antagonists; Opioid mu receptor agonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Premature ejaculation
Most Recent Events
- 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
- 19 Nov 2015 Aytu BioScience receives US FDA approval to initiate phase III studies in Premature ejaculation
- 20 May 2015 No recent reports on development identified - Phase-III for Premature ejaculation in Europe (PO)